ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression
1. ZyVersa's VAR 200 targets kidney disease by removing excess lipids. 2. Phase 2a trial for diabetic kidney disease is underway with results anticipated in Q4-2025. 3. Global kidney disease market is projected to expand from $18B in 2024 to $30B in 2034. 4. Research links specific lipid alterations to chronic kidney damage in Alport Syndrome. 5. ZyVersa aims to address renal failure statistics with innovative therapies.